[{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from an Ongoing Phase I\/II CYPIDES Trial of ODM-208 Presented at ASCO-GU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Orion Corporation"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$290.0 million","newsHeadline":"Orion and MSD Announce Global Collaboration for The Development and Commercialisation Of ODM-208, An Investigational Steroid Synthesis Inhibitor for The Treatment of Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Orion Corporation"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Business Finland","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Faron receives grant from Business Finland","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Faron Pharmaceuticals"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Safety and Efficacy Results from Part I of MATINS Study Presented in Poster at ASCO20 Virtual","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Faron Pharmaceuticals"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bexmarilimab Results Published in CCR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Faron Pharmaceuticals"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faron Provides Update on Bexmarilimab Development Program Ahead of R&D Day","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Faron Pharmaceuticals"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faron Announces Upcoming Presentation of Biomarker Analysis from Patients in MATINS Trial at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Faron Pharmaceuticals"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faron Presents Results from Melanoma Cohort of MATINS Trial at 18th Congress of the European Association of Dermato-Oncology (EADO)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Faron Pharmaceuticals"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faron Updates Positive Clinical Data from Phase I\/II BEXMAB Study of Bexmarilimab in Relapsed\/Refractory AML and MDS BEXMAB Study Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Faron Pharmaceuticals"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Faron Pharmaceuticals"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed\/Refractory AML and HMA-Refractory MDS Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Faron Pharmaceuticals"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Faron Pharmaceuticals"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inside Information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as Part of Phase 2 of BEXMAB Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Faron Pharmaceuticals"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Faron Pharmaceuticals"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
ODM-208 is a novel, oral, non-steroidal and selective inhibitor of CYP11A1 enzyme developed by Orion for the treatment of prostate cancer. ODM-208 suppresses the production of all steroid hormones and their precursors that may activate AR signalling pathway.
FP-1305 (bexmarilimab) is a monoclonal antibody that binds to Clever-1. It is being evaluated in phase 1/2 clinical trials for the treatment of acute myeloid leukemia, myelodysplastic syndromes & chronic myelomonocytic leukemia.
FP-1305 (bexmarilimab) is a CLEVER-1 binder, which is under phase 1/2 clinical development in combination with azacitidine & venetoclax for the treatment of acute myeloid leukemia, myelodysplastic syndromes & chronic myelomonocytic leukemia.
FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases, which is investigated for the treatment of relapsed/refractory AML and HMA-refractory MmDS patients.
FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases, which is investigated for the treatment of relapsed/refractory AML and HMA-refractory MmDS patients.
U.S. FDA has granted Orphan Drug Designation to Faron Pharmaceuticals' wholly owned asset bexmarilimab, for the treatment of acute myeloid leukemia. ODD will further help bexmarilimab program by offering clinical development and commercialization benefits.
FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system).
Of 11 patients, 4 experienced clinical benefit - 1 patient had a partial response after two cycles of bexmarilimab (tumor growth reduced by 40% from baseline) but was discontinued before a confirmatory scan was performed. 3 patients had stable disease.
The conclusion from analysis is that, when used together, IFNy and TNFa are highly predictive of response to bexmarilimab (P < 0.0001), and patients with low IFNy and TNFa levels experienced significantly higher clinical benefit following treatment with bexmarilimab.